See more : Fwusow Industry Co., Ltd. (1219.TW) Income Statement Analysis – Financial Results
Complete financial analysis of Prelude Therapeutics Incorporated (PRLD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Prelude Therapeutics Incorporated, a leading company in the Biotechnology industry within the Healthcare sector.
- santec Holdings Corporation (6777.T) Income Statement Analysis – Financial Results
- Nestbuilder.com Corp. (NBLD) Income Statement Analysis – Financial Results
- Substrate Artificial Inteligence, S.A. (SAI.MC) Income Statement Analysis – Financial Results
- GoldON Resources Ltd. (GLD.V) Income Statement Analysis – Financial Results
- Crown Resorts Limited (CWLDY) Income Statement Analysis – Financial Results
Prelude Therapeutics Incorporated (PRLD)
About Prelude Therapeutics Incorporated
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers; PRT3645, a brain penetrant molecule that potently and selectively targets CDK4/6; and PRT-K4 that is in preclinical stage for solid tumors. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.17M | 3.04M | 2.24M | 542.00K | 382.00K | 149.00K |
| Gross Profit | -1.17M | -3.04M | -2.24M | -542.00K | -382.00K | -149.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 103.39M | 92.89M | 86.78M | 48.18M | 24.28M | 12.62M |
| General & Administrative | 28.88M | 30.65M | 26.96M | 10.59M | 3.83M | 2.35M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 28.88M | 30.65M | 26.96M | 10.59M | 3.83M | 2.35M |
| Other Expenses | 0.00 | 8.10M | 2.04M | 1.83M | 539.00K | 295.00K |
| Operating Expenses | 132.28M | 123.54M | 113.74M | 58.76M | 28.11M | 14.98M |
| Cost & Expenses | 132.28M | 123.54M | 113.74M | 58.76M | 28.11M | 14.98M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.17M | 3.04M | 2.24M | 542.00K | 382.00K | 149.00K |
| EBITDA | -131.11M | -122.22M | -112.82M | -58.22M | -27.73M | -14.83M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -132.28M | -123.54M | -113.74M | -58.76M | -28.11M | -14.98M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 10.45M | 8.10M | 2.04M | 1.83M | 539.00K | 295.00K |
| Income Before Tax | -121.83M | -115.44M | -111.69M | -56.93M | -27.57M | -14.68M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -8.10M | -915.00K | 335.70K | 210.14K | 295.00K |
| Net Income | -121.83M | -107.34M | -110.78M | -56.93M | -27.57M | -14.68M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.02 | -2.27 | -2.33 | -1.30 | -0.85 | -0.46 |
| EPS Diluted | -2.02 | -2.27 | -2.33 | -1.30 | -0.85 | -0.46 |
| Weighted Avg Shares Out | 60.36M | 47.37M | 47.60M | 43.71M | 32.40M | 32.11M |
| Weighted Avg Shares Out (Dil) | 60.36M | 47.37M | 47.60M | 43.71M | 32.40M | 32.11M |
Prelude Therapeutics Announces Launch of Proposed Public Offering
Prelude Therapeutics Announces Third Quarter 2020 Financial Results
Source: https://incomestatements.info
Category: Stock Reports